Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 96 Präparate · 6744 Quellenpassagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) quinidine (HOS-085593) fusidic acid (HOS-086146) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) bepridil (HOS-085612) dronedarone (HOS-086144) alfuzosin (HOS-086139) lead (HOS-085592) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610) quinidine (HOS-085593) fusidic acid (HOS-086146) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) encainide (HOS-086145) flecainide (HOS-086203) propafenone (HOS-084530)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 12
HOS-086194 · Präparat HOS-083284
Pethidine, propoxyphene Ritonavir co-administration is likely to result in increased plasma concentrations of
norpethidine and propoxyphene and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 8a6ae25882a5a509c84c4394bf1df5c2cfab3523fadbd187fcb126d4ccd5fa49 · Zeichen 11028–11269 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 44
HOS-086407 · Präparat HOS-083284
Pethidine, propoxyphene Ritonavir co-administration is likely to result in increased plasma concentrations of
norpethidine and propoxyphene and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage c3f9c63e37098ad0d19dd1c60523e2aabef6ddd37f5c7d501e22116f2cd10e44 · Zeichen 11278–11529 im Abschnitt
Wechselwirkungen · Insuman
Insuman Rapid 40 IU/ml solution for injection in a vial Insuman Rapid 100 IU/ml solution for injection in a vial · Abschnitt 4.5 · PDF-Seite 5–6
HOS-088585 · Präparat HOS-083671
5
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 602a8c7eb20bd2e678e9e248b8f6ac28ef5053b6b03e745165f027f8762fb75a · Zeichen 151–498 im Abschnitt
Wechselwirkungen · Insuman
Insuman Rapid 100 IU/ml solution for injection in a cartridge Insuman Rapid SoloStar 100 IU/ml solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 16
HOS-088612 · Präparat HOS-083671
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140) glucose (HOS-088412) disopyramide (HOS-085595)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 0121d5df56b2a6e84d760a6414df4c03a5fcac4ba6433ca1c797ee593908d785 · Zeichen 0–443 im Abschnitt
Wechselwirkungen · Insuman
Insuman Basal 40 IU/ml suspension for injection in a vial Insuman Basal 100 IU/ml suspension for injection in a vial Insuman Basal 100 IU/ml suspension for injection in a cartridge Insuman Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 27
HOS-088632 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 1dc18158a535500ff3987627dbbd6593d04322294bf76173c702f592a4a97528 · Zeichen 100–444 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 15 100 IU/ml suspension for injection in a vial Insuman Comb 15 100 IU/ml suspension for injection in a cartridge Insuman Comb 15 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 39
HOS-088652 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clozapine (HOS-086149) disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140) danazol (HOS-085473) diazoxide (HOS-088588) glucagon (HOS-088589) isoniazid (HOS-088590) somatropin (HOS-088591) epinephrine (HOS-088592) terbutaline (HOS-085475) protease (HOS-085623) olanzapine (HOS-085937)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 18919877bb39ad0d4ea769fe50ee0dec48b2e438f4ee9db39eb8acbd3926e791 · Zeichen 100–890 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 25 40 IU/ml suspension for injection in a vial Insuman Comb 25 100 IU/ml suspension for injection in a vial Insuman Comb 25 100 IU/ml suspension for injection in a cartridge Insuman Comb 25 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 51
HOS-088670 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140) disopyramide (HOS-085595)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 1dc18158a535500ff3987627dbbd6593d04322294bf76173c702f592a4a97528 · Zeichen 100–444 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 30 100 IU/ml suspension for injection in a vial Insuman Comb 30 100 IU/ml suspension for injection in a cartridge Insuman Comb 30 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 64
HOS-088690 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 1dc18158a535500ff3987627dbbd6593d04322294bf76173c702f592a4a97528 · Zeichen 100–444 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 50 40 IU/ml suspension for injection in a vial Insuman Comb 50 100 IU/ml suspension for injection in a vial Insuman Comb 50 100 IU/ml suspension for injection in a cartridge Insuman Comb 50 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 76
HOS-088709 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 1dc18158a535500ff3987627dbbd6593d04322294bf76173c702f592a4a97528 · Zeichen 100–444 im Abschnitt
Wechselwirkungen · Insuman
Insuman Infusat 100 IU/ml solution for injection in a vial · Abschnitt 4.5 · PDF-Seite 87–88
HOS-088728 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
87
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 6a84ff0626c9919d561a1bd95164bec62f4a3e31e3e0c1aafdacee1ec49c5cc8 · Zeichen 100–499 im Abschnitt
Wechselwirkungen · Insuman
Insuman Implantable 400 IU/ml solution for infusion · Abschnitt 4.5 · PDF-Seite 99
HOS-088749 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 1dc18158a535500ff3987627dbbd6593d04322294bf76173c702f592a4a97528 · Zeichen 100–444 im Abschnitt
Wechselwirkungen · Lantus
Lantus 100 units/ml solution for injection in a vial Lantus 100 units/ml solution for injection in a cartridge Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 6
HOS-091008 · Präparat HOS-084169
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulfonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): disopyramide (HOS-085595) fluoxetine (HOS-085946) pentoxifylline (HOS-088586) propoxyphene (HOS-086140)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T11:08:00Z · SHA-256 675b799bf0c080ebd4fa5597f08423cd1cb573541330b2cc6a5cdd808c8fe620 · Passage 337e9f69643456df7d5334a7237887f6abebae1dc2e94ff2ba1eaea7ba060820 · Zeichen 103–446 im Abschnitt
Wechselwirkungen · Toujeo (previously Optisulin)
Toujeo 300 units/ml SoloStar, solution for injection in a pre-filled pen Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 7
HOS-091278 · Präparat HOS-084253
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include anti-hyperglycaemic medicinal products, angiotensin converting enzyme
(ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,
pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pentoxifylline (HOS-088586) propoxyphene (HOS-086140) fluoxetine (HOS-085946) disopyramide (HOS-085595)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T16:06:00Z · SHA-256 05d36a6d50acda15612619f58c6f2b433b88d383f261fed3243417274c24906d · Passage c064a130c604fec00826cc06f2901023f6056d8a53798dc96a7a8ce5c7024051 · Zeichen 103–448 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.